M.P.H., University of Washington, Epidemiology, 2002.
M.D., Cornell University, Medicine, 1997.
Dr. Casper divides his time between engaging in research, teaching and clinical care. His research efforts focus on the transmission, acquisition, natural history, pathophysiology and treatment of infection-associated cancers with a special focus on human herpesvirus 8 (HHV-8). His immunology work described the first comprehensively-validated serologic assay for detection of antibodies to HHV-8, the original description of neutralizing antibodies to HHV-8 and their role in development of Kaposi Sarcoma (KS), and the characterization of gamma-delta T-cell activity in persons with chronic HHV-infection. He then made the first descriptions of the symptoms and viral replication patterns of HHV-8-infected persons without KS. As part of this work, he studied HHV-8 transmission among couples discordant for HHV-8 infection, and also collaborated with researchers in HIV prevention studies to describe epidemiologic risk factors for acquiring HHV-8 in many different cohorts.
As part of his research into HHV-8, Dr. Casper described the successful use of antiviral therapy for the treatment of multicentric Castleman disease (MCD) and followed this by the first randomized trial of an antiviral against HHV-8. He also utilized information from a large primary HIV clinic to show that the majority of patients with KS in the highly active antiretroviral therapy era have persistent disease, despite the receipt of highly active antiretroviral therapy (HAART) and chemotherapy. This work has informed current and future studies evaluating the role of antiviral drugs in the treatment and prevention of infection-associated cancers.
In 2004, Dr. Casper initiated collaboration with physician-scientists at the Uganda Cancer Institute (UCI) and the Kampala Cancer Registry resulting in the formation of the UCI/Hutchinson Center Cancer Alliance. As Director of this program, based at the Fred Hutchinson Cancer Research Center, he established a translational clinical research site in Kampala. This site currently has 23 ongoing studies examining the control of HHV-8 replication, biomarkers for the prediction of KS development and successful treatment, the immunogenetics of infection-associated cancers, treatment of KS and Burkitt lymphoma, the role of nutrition in the development and treatment of infection-related cancers, and the discovery of novel pathogens associated with cancer. Under Dr. Casper's direction, research is being bolstered with the addition of a new cancer clinic and hospital, a quickly expanding training program, and a state-of-the-art molecular diagnostics laboratory.
American Practioners for Infection Control
Centers for Disease Control
Infectious Diseases Society of America
National Comprehensive Cancer Network
Honors and Awards
2007, Young Investigator Award, School of Medicine, University of Washington
2005, Clinical Scientist Development Award, Doris Duke Charitable Foundation
2001-2003, Special Citation for Fellows-in-Training, Infectious Diseases Society of America
2011, Top Doctor, Seattle Metropolitan Magazine, Fred Hutchinson Cancer Research Center
2005, Distinguished Investigator Award, Spanish Association of Rare Diseases/Castleman Disease
2002, Joel Meyers Infectious Diseases Scholarship Award, Fred Hutchinson Cancer Reserch Center
2005, Stephen L. Sacks Investigator Award, American Herpes Foundation
2010-2013, Associate Member, Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Clinical Research Division and Public Health Sciences Division
2007-2009, Assistant Professor, University of Washington, School of Public Health and Community Medicine, Epidemiology
2006, Lecturer, University of Washington, Conjoint 553: Clinical Management of HIV and STIs
2005-2010, Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research and Public Health Sciences Divisions, Vaccine and Infectious Disease Institute
2005-2009, Assistant Professor, University of Washington, School of Medicine, Medicine, Infectious Disease
2003, Subsitute Faculty, University of Washington, Introduction to Clinical Medicine
2002, Section Leader, University of Washington, School of Medicine, Human Biology 530: Epidemiology and Evidence-based Medicine
Dynamics of persistent oral cytomegalovirus shedding during primary infection in Ugandan infants.. The Journal of infectious diseases.. 2016.
Measurement of Circulating Phospholipid Fatty Acids: Association between Relative Weight Percentage and Absolute Concentrations.. Journal of the American College of Nutrition. :1-10.. 2016.
Infection-related cancers: prioritising an important and eliminable contributor to the global cancer burden.. The Lancet. Global health.. 2016.
Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(7):882-913.. 2016.
Glycemic Status and Infection Risk in Nondiabetic Autologous Hematopoietic Cell Transplantation Recipients.. Biological research for nursing.. 2016.
Prospective characterization of the risk factors for transmission and symptoms of primary human herpesvirus infections among Ugandan infants.. The Journal of infectious diseases.. 2016.
Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons.. Infectious agents and cancer. 11:7.. 2016.
Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy.. Journal of cancer epidemiology. 2016:2138259.. 2016.
Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda.. The Journal of infectious diseases.. 2015.
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(19):4294-304.. 2015.
Employee influenza vaccination in a large cancer center with high baseline compliance rates: comparison of carrot versus stick approaches.. American journal of infection control. 43(3):228-33.. 2015.
A Population-Level Evaluation of the Effect of Antiretroviral Therapy on Cancer Incidence in Kyadondo County, Uganda, 1999 - 2008.. Journal of acquired immune deficiency syndromes (1999).. 2015.
Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturation.. Advances in virology. 2015:687162.. 2015.
Nosocomial Transmission of Respiratory Syncytial Virus in an Outpatient Cancer Center.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2014.
Building capacity for sustainable research programmes for cancer in Africa.. Nature reviews. Clinical oncology.. 2014.
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres.. British journal of haematology.. 2014.
Accelerated suppression of primary EBV infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 2014.
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.. The lancet oncology. 15(9):966-74.. 2014.
Oral HHV-8 replication among women in Mombasa, Kenya.. Journal of medical virology.. 2014.
Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy.. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 60(2):127-32.. 2014.
Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.. Current opinion in oncology. 25(5):495-502.. 2013.
Population-based assessment of kaposi sarcoma-associated herpesvirus DNA in plasma among Ugandans.. Journal of medical virology. 85(9):1602-10.. 2013.
A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2013.